Organoid as a promising tool for primary liver cancer research: a comprehensive review
Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Cur...
Saved in:
| Published in: | Cell & bioscience Vol. 14; no. 1; pp. 107 - 23 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
27-08-2024
BioMed Central BMC |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine. |
|---|---|
| AbstractList | Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine. Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine. Keywords: Primary Liver Cancer, Organoid, Tumor Research, Drug screening, Personalized medicine, Translational research Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine.Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine. Abstract Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and the heterogeneity of tumors, patients with liver cancer lack effective treatment options, which leads to rapid progression and metastasis. Currently, preclinical models of PLC fall short of clinical reality and are limited in their response to disease progression and the effectiveness of drug therapy. Organoids are in vitro three-dimensional cultured preclinical models with a high degree of heterogeneity that preserve the histomorphological and genomic features of primary tumors. Liver cancer organoids have been widely used for drug screening, new target discovery, and precision medicine; thus representing a promising tool to study PLC. Here, we summarize the progress of research on liver cancer organoids and their potential application as disease models. This review provides a comprehensive introduction to this emerging technology and offers new ideas for researchers to explore in the field of precision medicine. |
| Audience | Academic |
| Author | Zhang, Qichen Wei, Jiayun Zhang, Yue Hu, Xuekai Liu, Pinyan Zheng, Qiuxia Ni, Jingman Yao, Jia |
| Author_xml | – sequence: 1 givenname: Xuekai surname: Hu fullname: Hu, Xuekai organization: School of Pharmacy, Lanzhou University, Lanzhou, 730000, China – sequence: 2 givenname: Jiayun surname: Wei fullname: Wei, Jiayun organization: The First Hospital of Lanzhou University, Lanzhou, 730000, China – sequence: 3 givenname: Pinyan surname: Liu fullname: Liu, Pinyan organization: The First Hospital of Lanzhou University, Lanzhou, 730000, China – sequence: 4 givenname: Qiuxia surname: Zheng fullname: Zheng, Qiuxia organization: The First school of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China – sequence: 5 givenname: Yue surname: Zhang fullname: Zhang, Yue organization: The First school of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China – sequence: 6 givenname: Qichen surname: Zhang fullname: Zhang, Qichen organization: The First school of Clinical Medicine, Lanzhou University, Lanzhou, 730000, China – sequence: 7 givenname: Jia surname: Yao fullname: Yao, Jia email: yaoj06@lzu.edu.cn, yaoj06@lzu.edu.cn, yaoj06@lzu.edu.cn, yaoj06@lzu.edu.cn organization: The First Hospital of Lanzhou University, No. 1 West Donggang Road, Lanzhou, Gansu, 730000, P. R. China. yaoj06@lzu.edu.cn – sequence: 8 givenname: Jingman surname: Ni fullname: Ni, Jingman email: nijm@lzu.edu.cn, nijm@lzu.edu.cn, nijm@lzu.edu.cn organization: School of Pharmacy, Lanzhou University, No. 199 West Donggang Road, Lanzhou, Gansu, 730000, P. R. China. nijm@lzu.edu.cn |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39192365$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktr3DAQx0VJadJtvkAPxdBLe3CqpyX1EkLoYyEQ6OsqZEn2KtjWVvJu22_fSXdbYqiEGDHzn59mBj1FJ1OaAkLPCb4gRDVvCmFCqhpTXmNClazFI3RGMRc1k5icPLifovNS7jAsrgmW4gk6ZZpoyhpxhr7d5t5OKfrKlspW25zGWOLUV3NKQ9WlDK442vyrGuI-5MrZyYHJoQSb3eYt5Lg0bnPYhKmAAiL7GH48Q487O5RwfrQr9PX9uy_XH-ub2w_r66ub2nOs5loqppwVViglueJt2wgGp2HE8yAwIxoz6jtJqWqoZl3HGhKEc5RLxb1u2QqtD1yf7J05lmqSjeaPI-Xe2DxHNwTTAIQKIrj2govQKtsq5XmrPSPwIAPW5YG13bVj8C5Mc7bDArqMTHFj-rQ3hDCuhNBAeHUk5PR9F8psYJguDIOdQtoVw7CWSlABs1-hlwdpb6G2OHUJkO5ebq4UVkw2Wt6rLv6jgu3DGB18iC6Cf5HwepEAmjn8nHu7K8WsP39aal887Pdfo38_B_sNVP67Qw |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. The Author(s) 2024 2024 |
| Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: The Author(s) 2024 2024 |
| DBID | NPM ISR 7X8 5PM DOA |
| DOI | 10.1186/s13578-024-01287-5 |
| DatabaseName | PubMed Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-3701 |
| EndPage | 23 |
| ExternalDocumentID | oai_doaj_org_article_6228251549d545eb8ab88d4b9d316313 A808376972 39192365 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: First Clinical Medical School, Lanzhou University grantid: ldyyyn2019-03 – fundername: National Natural Science Foundation of China grantid: 32160230 – fundername: Talent Innovation and Entrepreneurship Project in Chengguan District, Lanzhou City, Gansu Province grantid: 2022RCCX0024 |
| GroupedDBID | -A0 0R~ 3V. 53G 5VS 7X7 8FE 8FH 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C24 C6C CCPQU DIK EBLON EBS FYUFA GROUPED_DOAJ HCIFZ HMCUK HYE IAO IGS IHR ISR ITC KQ8 LK8 M7P M~E NPM O5R O5S OK1 PGMZT PIMPY PQQKQ PROAC RBZ ROL RPM RSV SBL SOJ TUS UKHRP 7X8 5PM |
| ID | FETCH-LOGICAL-d408t-7838ca5a5887484bb653b65631d4e50319032df72286293ff361e5cc24784d9b3 |
| IEDL.DBID | RPM |
| ISSN | 2045-3701 |
| IngestDate | Tue Oct 22 15:07:37 EDT 2024 Tue Sep 17 21:26:49 EDT 2024 Sat Oct 26 04:29:36 EDT 2024 Thu Sep 19 02:10:28 EDT 2024 Tue Sep 17 03:58:19 EDT 2024 Sat Sep 28 21:36:09 EDT 2024 Sat Nov 02 12:29:47 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Organoid Translational research Tumor Research Primary Liver Cancer Drug screening Personalized medicine |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-d408t-7838ca5a5887484bb653b65631d4e50319032df72286293ff361e5cc24784d9b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11348559/ |
| PMID | 39192365 |
| PQID | 3097852592 |
| PQPubID | 23479 |
| PageCount | 23 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6228251549d545eb8ab88d4b9d316313 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11348559 proquest_miscellaneous_3097852592 gale_infotracmisc_A808376972 gale_infotracacademiconefile_A808376972 gale_incontextgauss_ISR_A808376972 pubmed_primary_39192365 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-08-27 |
| PublicationDateYYYYMMDD | 2024-08-27 |
| PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-27 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Cell & bioscience |
| PublicationTitleAlternate | Cell Biosci |
| PublicationYear | 2024 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| SSID | ssj0000491075 |
| Score | 2.3766165 |
| SecondaryResourceType | review_article |
| Snippet | Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation donors and... Abstract Primary liver cancer (PLC) is one of the most common malignant gastrointestinal tumors worldwide. Limited by the shortage of liver transplantation... |
| SourceID | doaj pubmedcentral proquest gale pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 107 |
| SubjectTerms | Cancer Development and progression Diagnosis Drug screening Gastrointestinal diseases Liver Liver cancer Metastasis Oncology, Experimental Organoid Personalized medicine Primary Liver Cancer Review Translational research Transplantation Tumor Research |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA4qCF7Et-uLKIKnYtskTerNJ3rx4AtvIWlSd0Va2O4e_PfONFW2ePDioZdmWpKZdB5lvi-EHCdOidxBdVJICQWKhYLVcq8iDqmCLLmH76_9dfEo71_V1TXS5Pwc9YU9YYEeOCjuNEtbdCWUMQ6CvbfKWKUct7ljkEokgeczzmaKqfeQ90JdI75RMio7bRLkdYkgJEXok2UkOpb-3754Jhj1GyVnIs_NClnuUkZ6Hqa6SuZ8tUYWwyGSn-vkpYVT1iNHTUMNhdeD6SAg0Uldf1DISeFWyyhBP7AHgxZo5zHtWH6GZ_AM9pWP_TD0stOAZtkgzzfXT5e3UXdaQuR4rCaRVEwVRhgBboMrbm0mGFygI8e9QLBSzFJXStBnBjG-LFmWeFEUKZeKu9yyTbJQ1ZXfJtQw63NmS4FA06RMjEwL4XlqncmZieMBuUDN6W76Gimq2xtgON0ZTv9luAE5Qr1rJKGosMvlzUybRt89PuhzBYmhzHKZDshJJ1TWYIHCdKABmCfyVvUk93qSoOqiN3z4bV6NQ9haVvl62miGSBYBVSDIbAVz_yyM5ZgAZ2JAVG8j9FbeH6lGw5akOwHVKSjXdv5DV7tkKW13Lng1uUcWJuOp3yfzjZsetPv-C2nAA34 priority: 102 providerName: Directory of Open Access Journals |
| Title | Organoid as a promising tool for primary liver cancer research: a comprehensive review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39192365 https://www.proquest.com/docview/3097852592 https://pubmed.ncbi.nlm.nih.gov/PMC11348559 https://doaj.org/article/6228251549d545eb8ab88d4b9d316313 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFLWYSkhsEG8G2sogJFbpjF-xw65PwQKEKCB2kV_pTDVN0GRm0b_vvU6CJmLXRTaxEzm-N_a50TknhHxgwagiQHXitYYCxUHB6mQ0mQSooCsZ4f1Lny4u9bc_5uwcbXLyQQuTSPveLY_q1c1RvVwkbuXfGz8beGKz719PGRPoaVLMJmQC4HCnRr_uMC_UNGpQyJh81jL0dMlgO8pwPdaZ6h36_1-HdzaiMUlyZ9e5eEIe93CRHnfDekoexPoZedj9QPL2OfmdpJTNMlDbUkvh9hA22IzopmlWFPAonEpuEnSF_AvqMcZr2jv8LD7BNcgpX8dFx2OnnZLlBfl1cf7z9HPW_ykhC3JuNpk2wnirrIIlQxrpXK4EHLlgQUaFQqW54KHSnEMBU4iqEjmLynsutZGhcOIl2aubOr4m1AoXC-EqhSJTVjGruVdRchdsIex8PiUnOHNlP_wS7anTiWZ9VfZBKnOeJLFQewZAaNEZ64wJ0hVBAP5jYkre47yXaEBRI8Plym7btvxy-aM8NgAKdV5oPiUf-05VAxHwthcMwDjRs2rUc3_UE6baj5rfDeEtsQlpZXVstm0pUMWioAKEPq-6cP97MFEg-M3VlJhRIoyefNwC-ZoMuof8fHP_S9-SRzzlK6xjep_sbdbbeEAmbdgeps8Ghynn7wBV_AUD |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53800,53802 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoEYIL78JCAYOQOKWbxHbscCulVSvaCtGCuFl-pbtom6DN7oF_z4yToI249ZCLPZb8GNsz0fd9JuR95pUoPWQnTkpIUCwkrJYHlXAIFWTFA-y_-OviQp7_VJ8PUSanGLgwEbTv7HyvXlzv1fNZxFb-vnbTASc2_Xp2kGUMNU3K6Ra5DRs2TTey9F9d1AtZjRg4MqqYthmquiRwISV4IstE9Br9_5_EG1fRGCa5ce8cPbhpjx-S-32kSfe7-kfkVqgfkzvd25N_npAfkYXZzD01LTUU-gUrDvcYXTXNgkIoC0VRiIIuELpBHbrHkvbiQLOP0Abh6Msw6yDwtCPBPCXfjw4vD46T_pGFxPNUrRKpmHJGGAGnDVfc2kIw-AqWeR4EcpxSlvtK5jnkPiWrKlZkQTiXc6m4Ly3bIdt1U4fnhBpmQ8lsJZCfmlWZkbkTgefWm5KZNJ2QTzjluu--RmXrWNAsr3Q_W7rII5sW0lYPwV2wylilPLelZxA6ZmxC3uGCadSuqBEcc2XWbatPLr7pfQXxpCxKmU_Ih96oamDpnOm5BtBPlLsaWe6OLGGq3aj67eAXGqsQkVaHZt1qhgQYAckj2Dzr_OTfwFiJcXMhJkSNPGg08nENOE7U9h4c5cXNm74hd48vz0716cn5l5fkXh6dHo5DuUu2V8t1eEW2Wr9-HbfMX-oQGcs |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoEYhLeRa2FDAIiVOaxI_Y6a20XVEBVUUBcbP8SnfRNqk2uwf-PWMnQRtxg0Mu9ljyY2zPRN_3GaG3uZO8dJCdWCEgQTGQsBrmZcIgVBAV87D_4q-LS3H-Q56cBpmcw4ELE0H71swP6sX1QT2fRWzlzbVNB5xYevH5OM9p0DQp0xtXpVvoNmzajGxk6j-7yBcyGz7wZGSRtnlQdkngUkrCqSwS3uv0_30ab1xHY6jkxt0zvf8_vX6AdvqIEx91Ng_RLV8_Qne6Nyh_PUbfIxuzmTusW6wx9A1WHu4zvGqaBYaQFoqiIAVeBAgHtsFNlrgXCZodQpsAS1_6WQeFxx0Z5gn6Nj39evwh6R9bSBzL5CoRkkqrueZw6jDJjCk4ha-guWOeB65TRomrBCGQA5W0qmiRe24tYUIyVxq6i7brpvbPENbU-JKaigeeal7lWhDLPSPG6ZLqLJug92HaVd99FRSuY0GzvFL9jKmCRFYtpK8OgjxvpDZSOmZKRyGEzOkEvQmLpoKGRR1AMld63bbq7PKLOpIQV4qiFGSC3vVGVQPLZ3XPOYB-BtmrkeX-yBKm2o6qXw--oUJVQKbVvlm3igYiDIckEmyedr7yZ2C0DPFzwSdIjrxoNPJxDThP1PgenGXv35u-QncvTqbq09n5x-foHol-D6ei2Efbq-Xav0BbrVu_jLvmN8zXHEs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Organoid+as+a+promising+tool+for+primary+liver+cancer+research%3A+a+comprehensive+review&rft.jtitle=Cell+%26+bioscience&rft.au=Hu%2C+Xuekai&rft.au=Wei%2C+Jiayun&rft.au=Liu%2C+Pinyan&rft.au=Zheng%2C+Qiuxia&rft.date=2024-08-27&rft.issn=2045-3701&rft.eissn=2045-3701&rft.volume=14&rft.issue=1&rft.spage=107&rft_id=info:doi/10.1186%2Fs13578-024-01287-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-3701&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-3701&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-3701&client=summon |